MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
What are clinical trials for leukemia?
Clinical trials for leukemia are research studies designed to evaluate new treatments, therapies, or diagnostic methods for different types of leukemia, a group of cancers that affect the blood and bone marrow. These trials aim to discover more effective ways to treat leukemia, manage its symptoms, and improve patient outcomes. They may involve testing new drugs, combinations of existing treatments, targeted therapies, immunotherapies, or novel approaches like gene therapy.
Why are leukemia clinical trials important?
Leukemia clinical trials are crucial because they drive advancements in treatment by testing new therapies, improving existing ones, and exploring novel approaches to manage and potentially cure the disease. These trials provide essential data on the safety and effectiveness of new treatments, which can lead to better outcomes and fewer side effects compared to current options.
Types of clinical trials for leukemia
Researchers have a number of options available when it comes to choosing the type of clinical trial that should be used for a leukemia research study.
Diagnostic trials
Diagnostic trials in leukemia clinical research focus on developing or refining techniques for detecting and diagnosing the disease more accurately and earlier. These trials test new diagnostic tools, such as imaging technologies, blood tests, or genetic assays, to improve the precision of leukemia detection, identify specific subtypes, and monitor disease progression.
By enhancing diagnostic methods, these trials aim to enable earlier intervention, tailor treatments more effectively, and ultimately improve patient outcomes and survival rates.
Genetic and biomarkers studies
Genetic and biomarker studies in leukemia focus on identifying specific genetic mutations, variations, and molecular markers associated with the disease. By analyzing the genetic profile of leukemia cells and patients, researchers can uncover the underlying mechanisms that drive the disease's development and progression. This information is crucial for advancing personalized medicine, as it enables healthcare providers to tailor treatments to the unique genetic makeup of each patient.
Interventional trials
Interventional trials for leukemia actively test new treatments or therapeutic approaches by administering experimental drugs or therapies to participants. These trials evaluate the effectiveness and safety of new drugs, compare new treatments with standard options, explore combination therapies, and assess innovative strategies like stem cell transplants or gene therapy. They also help determine optimal dosages and administration schedules.
Prevention trials
Researchers can use prevention trials for leukemia to identify strategies to reduce the risk of developing the disease or to prevent its recurrence in patients who are in remission. These trials may test interventions such as medications, lifestyle changes, or vaccines in individuals at high risk for leukemia, such as those with a family history or predisposing conditions.
By evaluating these preventive measures, the trials seek to find effective ways to lower the incidence of leukemia or delay its onset, ultimately improving long-term outcomes and quality of life for those at risk.
Why participate in a leukemia clinical trial
Just as many clinical trials can pose risks or considerations, leukemia clinical trials can offer a number of benefits for participants too.
Participant benefits
Participating in a clinical trial for leukemia offers several benefits, including access to cutting-edge treatments and therapies that may not be available outside the trial. Participants receive close monitoring and care from specialized medical teams, which can lead to early detection of side effects and more personalized treatment adjustments.
Leukemia clinical trials also contribute to valuable research, advancing medical knowledge and supporting the development of better future treatments. Additionally, involvement in a trial provides an opportunity to potentially benefit from new interventions that could improve outcomes and quality of life.
Risks and considerations
When deciding whether to participate in a clinical trial for leukemia, it’s important to think about the risks and considerations, such as the potential for unknown side effects from experimental treatments, which may be worse or different from standard therapies. There is also the risk that the new treatment may not be effective, potentially leading to a lack of improvement or worsening of the condition.
Participants might also face rigorous schedules for medical visits and tests, which can be time consuming and inconvenient. It’s possible that participants could have uncertainties about coverage of trial-related expenses, as well as the emotional stress of navigating an experimental treatment.
Worried about the risks of participating in a clinical trial? Delve into our comprehensive guide to gain insights into the potential outcomes of participating. Learn about potential risks, benefits, and safety considerations to make an informed decision about your participation in a clinical trial.
Who can participate in a clinical trial for leukemia?
Specific criteria for involvement in a leukemia clinical trial depends on the trial’s objectives and design, but researchers often include factors such as the type and stage of leukemia, overall health, and prior treatments. Some trials may focus on particular age groups, such as children or adults, while others might target specific genetic mutations or risk factors. For most leukemia clinical trials, a leukemia diagnosis or a high risk of developing it is usually the first requirement.
In addition to patients with active leukemia, some trials may also include healthy volunteers for comparison purposes or individuals in remission to test preventive measures or recurrence interventions.
What to expect when participating in a leukemia clinical trial
When participating in a clinical trial for leukemia, you can expect to undergo a detailed screening process to confirm eligibility and provide informed consent about the study's purpose, procedures, risks, and benefits. You may receive experimental treatments or therapies, and will be closely monitored through regular medical visits, tests, and assessments to evaluate the effectiveness and safety of the intervention.
The trial may involve strict protocols, including rigorous schedules and adherence to treatment regimens. While participation in a leukemia clinical trial potentially offers access to innovative treatments and specialized care, it also involves the potential for unknown side effects and uncertainties regarding treatment outcomes.
How to enroll in a leukemia clinical trial
Enrolling in a clinical trial studying leukemia through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.